ARF6 Promotes AML Progression via Activation of PI3K/AKT/mTOR Signaling.

ABSTRACT:

Background

Acute myeloid leukemia (AML) represents a highly aggressive hematological malignancy characterized by a poor prognosis and a pressing demand for innovative diagnostic and prognostic biomarkers. Recent studies have indicated that ADP-ribosylation factor 6 (ARF6) is overexpressed across various cancer types; however, its specific role and implications in AML have yet to be thoroughly investigated.

Methods

To elucidate the clinical relevance and functional mechanisms of ARF6 in AML, we conducted an integrated analysis utilizing RNA sequencing data from The Cancer Genome Atlas (TCGA) alongside clinical samples and AML cell lines. The diagnostic potential of ARF6 was assessed through receiver operating characteristic curve analysis, and logistic regression was employed

SUBMITTER: Xu H 

PROVIDER: S-EPMC12021670 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature